Alnylam Pharmaceuticals
ALNY
657 hedge funds and large institutions have $43.1B invested in Alnylam Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 91 funds opening new positions, 266 increasing their positions, 216 reducing their positions, and 61 closing their positions.
49% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 61
42% more capital inflows, than outflows
Capital inflows: $2.55B | Capital outflows: $1.79B
23% more repeat investments, than reductions
Existing positions increased: 266 | Existing positions reduced: 216
5% more funds holding
Funds holding: 628 → 657 (+29)
1.81% more ownership
Funds ownership: 99.44% → 101.25% (+1.8%)
8% less call options, than puts
Call options by funds: $188M | Put options by funds: $203M
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$165M |
| 2 |
Holocene Advisors
New York
|
+$165M |
| 3 |
ClearBridge Investments
New York
|
+$152M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$146M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$137M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$177M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$173M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$148M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$100M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$89.2M |
ALNY Hedge Fund Activity: Q2 2025 in Review
657 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2025, worth a combined $43.1B — up 24% from $34.8B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new ALNY positions and 61 closed out — a net gain of 30 holders — while 266 added to existing stakes and 216 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $165M. The largest seller was AQR Capital Management, cutting an estimated $177M.
- 657 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2025, up from 628 in Q1 2025.
- Funds reported $43.1B of Alnylam Pharmaceuticals stock for Q2 2025, up 24% quarter-over-quarter.
- 91 funds opened new Alnylam Pharmaceuticals positions in Q2 2025 and 61 closed out, a net change of +30 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $165M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2025 was AQR Capital Management, an estimated $177M sold.
Based on aggregated 13F filings for Q2 2025.